Cytokine pathways and joint inflammation in rheumatoid arthritis.

By E. Choy, G. Panayi. New England Journal of Medicine, 2001

2,273 citations recorded by the source corpus.

Subfields: Hematology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/d954c77150fcad0724a30bd9770993a657345f35

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Rheumatology

1. S. Goldring
2. D. Tracey
3. M. Goldring
4. Lars Klareskog
5. J. Salfeld
6. P. Tak
7. E. Sasso
8. S. Rose‐John

Citations in the corpus

• Pathophysiology of chronic subdural haematoma: inflammation, angiogenesis and implications for pharmacotherapy (2017, background): “This is exemplified by conditions such as rheumatoid arthritis and asthma, where inflammatory cells contribute to joint destruction or airway oedema and remodelling, respectively [7, 8].”
• Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis (2006, methodology): “The models included treatment, visit day, and treatment-by-visit interaction as fixed effects, and we used an autoregressive (1) covariance to account for within-patient correlation over time (23).”
• Psychological Stress in Childhood and Susceptibility to the Chronic Diseases of Aging: Moving Towards a Model of Behavioral and Biological Mechanisms (2011, background): “However, it is becoming increasingly clear that chronic inflammation driven by macrophages and neutrophils also contributes to maintaining disease activity (Choy & Panayi, 2001; McGonagle & McDermott, 2006).”
• Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. (2006, background): “†Not reported in original publication; on file with US Food and Drug Administration (http://www.fda.gov/_Hlt94332169o_Hlt94332169hrms/dockets/ac/03/briefing /3930B1_01_C--_Hlt103512168_Hlt103512168HUMIRA.Med.Review.pdf).”
• Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. (2008, background): “At high concentrations of sTNF (N2 ng/mL), as measured in inflamed tissues (Van Deventer, 1997; Choy & Panayi, 2001), infliximab, etanercept and adalimumab all neutralized sTNF with comparable potencies.”
• Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study (2009, background): “Rheumatoid arthritis (RA) is a systemic inflammatory disease characterised by joint pain, stiffness and swelling due to synovial inflammation, as well as fatigue and limitations in physical function, and increased morbidity and mortality.”
• Platelets and the immune continuum (2011, background): “Rheumatoid arthritis is a chronic inflammatory and autoimmune disorder that typically affects the synovial joints of the hands and feet, leading to painful swelling and bone erosio”
• p38 MAP-kinases pathway regulation, function and role in human diseases. (2007, background): “In particular, TNFα, IL-1β and IL-6 are key players in rheumatoid arthritis, Crohn's disease (a subset of inflammatory bowel diseases), psoriasis, ankylosing spondylitis and chronic asthma [164–166].”